bioAffinity Technologies annual return on equity
2023
2024
2025
bioAffinity Technologies Return on Equity (ROE) Growth & History (BIAF)
bioAffinity Technologies's return on equity was −301.83% for fiscal 2025.
View full bioAffinity Technologies company overviewbioAffinity Technologies annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −301.83% | −59.38 pp |
| 2024 | 2024-12-31 | −242.44% | −142.60 pp |
| 2023 | 2023-12-31 | −99.84% | — |
bioAffinity Technologies quarterly return on equity
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −90.78% | — |
| Q1 2026 | 2026-03-31 | −66.47% | +65.19 pp |
| Q4 2025 | 2025-12-31 | −38.78% | +64.90 pp |
| Q3 2025 | 2025-09-30 | −149.31% | −88.25 pp |
| Q1 2025 | 2025-03-31 | −131.66% | −92.86 pp |
| Q4 2024 | 2024-12-31 | −103.68% | −63.63 pp |
| Q3 2024 | 2024-09-30 | −61.06% | −30.70 pp |
| Q2 2024 | 2024-06-30 | −48.57% | −28.98 pp |
| Q1 2024 | 2024-03-31 | −38.80% | −24.00 pp |
| Q4 2023 | 2023-12-31 | −40.06% | −25.89 pp |
| Q3 2023 | 2023-09-30 | −30.36% | — |
| Q2 2023 | 2023-06-30 | −19.59% | — |
| Q1 2023 | 2023-03-31 | −14.80% | — |
| Q4 2022 | 2022-12-31 | −14.17% | — |
bioAffinity Technologies return on equity trends
Between the periods ended 2023-12-31 and 2025-12-31, bioAffinity Technologies's return on equity decreased from −99.84% to −301.83%, a change of −201.98 percentage points. The latest reported quarter, Q2 2026, shows −90.78%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review bioAffinity Technologies source filings ↗